Real Impact for Patients
Now is the time. There is a growing clinical body of evidence which suggests antibodies that optimally target misfolded proteins can result in clinically meaningful benefit for patients. With a growing pipeline of programs based on this scientific approach, Prothena is advancing a number of novel therapeutics for rare peripheral amyloid and neurodegenerative diseases.